Skip to main content

Advertisement

SpringerLink
Log in

Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis

  • Myeloproliferative Neoplasms (B Stein, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The purpose of this review is to help doctors in the management of patients with post-polycythemia (PPV) and post-essential thrombocythemia (PET) myelofibrosis (MF) facing diagnostic criteria, prognostication, and treatment possibilities.

Recent Findings

Diagnostic criteria of primary myelofibrosis (PMF) have been recently updated from the WHO classification. A clear-cut distinction between pre-fibrotic and overt PMF has been done. Concerning PPV and PET MF, the criteria come from 2008. Prognostication of PMF has been well established on clinical criteria, but recent molecular acquisitions will improve the strategy. For PPV and PET MF, the new MYSEC-PM is helpful for prediction of survival. JAK2-inhibitors and stem cell transplant are the two critical therapeutic approaches in myelofibrosis.

Summary

Differences between PMF and SMF substantiate the efforts underway to adequately stratify SMF patients with ad hoc prognostic tools and to use such categorization to evaluate available treatment modalities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Passamonti F, Maffioli M. Update from the latest WHO classification of MPNs: a user’s manual. Hematology Am Soc Hematol Educ Program. 2016;2016(1):534–42.

    PubMed  Google Scholar 

  2. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895–901.

    Article  PubMed  CAS  Google Scholar 

  3. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.

    Article  PubMed  CAS  Google Scholar 

  4. Jeryczynski G, Thiele J, Gisslinger B, Wolfler A, Schalling M, Gleiss A, et al. Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: the impact of minor clinical diagnostic criteria on the outcome of the disease. Am J Hematol. 2017;92(9):885–91.

    Article  PubMed  CAS  Google Scholar 

  5. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761–70.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Tefferi A, Lasho TL, Guglielmelli P, Finke CM, Rotunno G, Elala Y, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2016;1(1):21–30.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29(23):3179–84.

    Article  PubMed  Google Scholar 

  8. Guglielmelli P, Pacilli A, Rotunno G, Rumi E, Rosti V, Delaini F, et al. Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood. 2017;129:3227–36.

    Article  PubMed  CAS  Google Scholar 

  9. Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, et al. MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol. 2017; https://doi.org/10.1200/JCO.2017.76.4886.

  10. Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22(2):437–8.

    Article  PubMed  CAS  Google Scholar 

  11. Barbui T, Thiele J, Gisslinger H, Finazzi G, Carobbio A, Rumi E, et al. Masked polycythemia vera (mPV): results of an international study. Am J Hematol. 2014;89(1):52–4.

    Article  PubMed  CAS  Google Scholar 

  12. Passamonti F, Rumi E, Caramella M, Elena C, Arcaini L, Boveri E, et al. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood. 2008;111(7):3383–7.

    Article  PubMed  CAS  Google Scholar 

  13. Rumi E, Passamonti F, Della Porta MG, Elena C, Arcaini L, Vanelli L, et al. Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. J Clin Oncol. 2007;25(35):5630–5.

    Article  PubMed  Google Scholar 

  14. Rumi E, Passamonti F, Pietra D, Della Porta MG, Arcaini L, Boggi S, et al. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer. 2006;107(9):2206–11.

    Article  PubMed  CAS  Google Scholar 

  15. Rumi E, Passamonti F, Picone C, Della Porta MG, Pascutto C, Cazzola M, et al. Disease anticipation in familial myeloproliferative neoplasms. Blood. 2008;112(6):2587–8. author reply 8–9

    Article  PubMed  CAS  Google Scholar 

  16. Maffioli M, Genoni A, Caramazza D, Mora B, Bussini A, Merli M, et al. Looking for CALR mutations in familial myeloproliferative neoplasms. Leukemia. 2014;28(6):1357–60.

    Article  PubMed  CAS  Google Scholar 

  17. Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507–13. quiz 615

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010;24(9):1574–9.

    Article  PubMed  CAS  Google Scholar 

  19. Tiribelli M, Barraco D, De Marchi F, Marin L, Medeot M, Damiani D, et al. Clinical factors predictive of myelofibrotic evolution in patients with polycythemia vera. Ann Hematol. 2015;94(5):873–4.

    Article  PubMed  Google Scholar 

  20. Alvarez-Larran A, Bellosillo B, Martinez-Aviles L, Saumell S, Salar A, Abella E, et al. Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients. Br J Haematol. 2009;146(5):504–9.

    Article  PubMed  CAS  Google Scholar 

  21. Alvarez-Larran A, Kerguelen A, Hernandez-Boluda JC, Perez-Encinas M, Ferrer-Marin F, Barez A, et al. Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. Br J Haematol. 2016;172(5):786–93.

    Article  PubMed  CAS  Google Scholar 

  22. Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Randi ML, et al. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood. 2012;119(10):2239–41.

    Article  PubMed  CAS  Google Scholar 

  23. Barraco D, Cerquozzi S, Hanson CA, Ketterling RP, Pardanani A, Gangat N, et al. Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations. Blood Cancer J. 2017;7(3):e538.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Abdulkarim K, Ridell B, Johansson P, Kutti J, Safai-Kutti S, Andreasson B. The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera. Eur J Haematol. 2011;86(2):148–55.

    Article  PubMed  Google Scholar 

  25. Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224–32.

    Article  PubMed  Google Scholar 

  26. Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110(3):840–6.

    Article  PubMed  CAS  Google Scholar 

  27. Passamonti F, Rumi E, Arcaini L, Boveri E, Elena C, Pietra D, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica. 2008;93(11):1645–51.

    Article  PubMed  Google Scholar 

  28. Rumi E, Pietra D, Guglielmelli P, Bordoni R, Casetti I, Milanesi C, et al. Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. Blood. 2013;121(21):4388–95.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  29. Elala YC, Lasho TL, Gangat N, Finke C, Barraco D, Haider M, et al. Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia. Am J Hematol. 2016;91(5):503–6.

    Article  PubMed  CAS  Google Scholar 

  30. Barraco D, Cerquozzi S, Hanson CA, Ketterling RP, Pardanani AD, Gangat N, et al. Cytogenetic findings in WHO-defined polycythaemia vera and their prognostic relevance. Br J Haematol 2017.

  31. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703–8.

    Article  PubMed  CAS  Google Scholar 

  32. •• Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia. 2017. Integrated clinical-molecular prognostic model in SMF.;31:2726–31.

    Article  PubMed  CAS  Google Scholar 

  33. Masarova L, Bose P, Daver N, Pemmaraju N, Newberry KJ, Manshouri T, et al. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. Leuk Res. 2017;59:110–6.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  34. Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia. 2008;22(5):905–14.

    Article  PubMed  CAS  Google Scholar 

  35. Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood. 2010;115(4):778–82.

    Article  PubMed  CAS  Google Scholar 

  36. Caramazza D, Begna KH, Gangat N, Vaidya R, Siragusa S, Van Dyke DL, et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia. 2011;25(1):82–8.

    Article  PubMed  CAS  Google Scholar 

  37. Caramazza D, Hussein K, Siragusa S, Pardanani A, Knudson RA, Ketterling RP, et al. Chromosome 1 abnormalities in myeloid malignancies: a literature survey and karyotype-phenotype associations. Eur J Haematol. 2010;84(3):191–200.

    Article  PubMed  CAS  Google Scholar 

  38. Caramazza D, Ketterling RP, Knudson RA, Hanson CA, Siragusa S, Pardanani A, et al. Trisomy 11: prevalence among 22,403 unique patient cytogenetic studies and clinical correlates. Leukemia. 2010;24(5):1092–4.

    Article  PubMed  CAS  Google Scholar 

  39. Wassie E, Finke C, Gangat N, Lasho TL, Pardanani A, Hanson CA, et al. A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients. Br J Haematol. 2015;169(1):71–6.

    Article  PubMed  CAS  Google Scholar 

  40. Rotunno G, Pacilli A, Artusi V, Rumi E, Maffioli M, Delaini F, et al. Epidemiology and clinical relevance of mutations in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study on 359 patients of the AGIMM group. Am J Hematol. 2016;91:681–6.

    Article  PubMed  CAS  Google Scholar 

  41. Li B, Xu J, Li C, Gale RP, Xu Z, Qin T, et al. Cytogenetic studies and their prognostic contribution in 565 Chinese patients with primary myelofibrosis. Am J Hematol. 2014;89(11):1043–6.

    Article  PubMed  Google Scholar 

  42. Gangat N, Tefferi A, Thanarajasingam G, Patnaik M, Schwager S, Ketterling R, et al. Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance. Eur J Haematol. 2009;83:17–21.

    Article  PubMed  CAS  Google Scholar 

  43. Tang G, Hidalgo Lopez JE, Wang SA, Hu S, Ma J, Pierce S, et al. Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera. Haematologica. 2017;102:1511–8.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Vaidya R, Caramazza D, Begna KH, Gangat N, Van Dyke DL, Hanson CA, et al. Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival. Blood. 2011;117(21):5612–5.

    Article  PubMed  CAS  Google Scholar 

  45. Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014;28(7):1472–7.

    Article  PubMed  CAS  Google Scholar 

  46. Passamonti F, Mora B, Giorgino T, Guglielmelli P, Cazzola M, Maffioli M, et al. Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients. Leukemia 2016.

  47. Beauverd Y, Alimam S, McLornan DP, Radia DH, Harrison CN. Disease characteristics and outcomes in younger adults with primary and secondary myelofibrosis. Br J Haematol. 2016;175:37–42.

    Article  PubMed  CAS  Google Scholar 

  48. Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martinez-Trillos A, Casetti I, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014;124(7):1062–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  49. Passamonti F, Mora B, Giorgino T, Guglielmelli P, Cazzola M, Maffioli M, et al. Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients. Leukemia. 2017;31(4):970–3.

    Article  PubMed  CAS  Google Scholar 

  50. Pietra D, Rumi E, Ferretti VV, Buduo CA, Milanesi C, Cavalloni C, et al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia. 2016;30(2):431–8.

    Article  PubMed  CAS  Google Scholar 

  51. Finazzi G, Carobbio A, Guglielmelli P, Cavalloni C, Salmoiraghi S, Vannucchi AM, et al. Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. Blood. 2014;124(16):2611–2.

    Article  PubMed  CAS  Google Scholar 

  52. Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27(9):1861–9.

    Article  PubMed  CAS  Google Scholar 

  53. Tefferi A, Guglielmelli P, Lasho TL, Rotunno G, Finke C, Mannarelli C, et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia. 2014;28(7):1494–500.

    Article  PubMed  CAS  Google Scholar 

  54. Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392–7.

    Article  PubMed  Google Scholar 

  55. •• Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, et al. MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol. 2018;36(4):310–8. Integrated clinical-molecular prognostic model in PMF.

    Article  PubMed  Google Scholar 

  56. Hernandez-Boluda JC, Pereira A, Correa JG, Alvarez-Larran A, Ferrer-Marin F, Raya JM, et al. Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis. Leukemia 2017.

  57. Gowin K, Coakley M, Kosiorek H, Mesa R. Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera/essential thrombocytosis myelofibrosis. Haematologica. 2016;101:e405–6.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Hernandez-Boluda JC, Pereira A, Gomez M, Boque C, Ferrer-Marin F, Raya JM, et al. The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis. Haematologica. 2014;99(4):e55–7.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Tefferi A, Saeed L, Hanson CA, Ketterling RP, Pardanani A, Gangat N. Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis. Leukemia. 2017;31:2851–2.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  60. Masarova L, Bose P, Pemmaraju N, Daver N, Cortes JE, Estrov Z, et al. Validation of the myelofibrosis secondary to PV and ET-prognostic model in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: MD Anderson Cancer Center. Blood. 2017;130(Suppl 1):4205.

    Google Scholar 

  61. Kroger N, Giorgino T, Scott BL, Ditschkowski M, Alchalby H, Cervantes F, et al. Impact of allogeneic stem cell transplantation on survival of patients less than 65 years with primary myelofibrosis. Blood. 2015;125:3347–50.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  62. •• Kroger NM, Deeg JH, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T, et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia. 2015. Indication and management of allogeneic stem cell transplantation in PMF.;29:2126–33.

    Article  PubMed  CAS  Google Scholar 

  63. Passamonti F, Maffioli M, Caramazza D. New generation small-molecule inhibitors in myeloproliferative neoplasms. Curr Opin Hematol. 2012;19(2):117–23.

    Article  PubMed  CAS  Google Scholar 

  64. Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012;120(6):1202–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  65. • Passamonti F, Maffioli M, Cervantes F, Vannucchi A, Morra E, Barbui T, et al. Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood. 2014. Impact on MF natural history of ruxoltinib.;123:1833–5.

    Article  PubMed  CAS  Google Scholar 

  66. Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Sirulnik A, Stalbovskaya V, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122:4047–53.

    Article  PubMed  CAS  Google Scholar 

  67. Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D, et al. Phase 3 randomized trial of momelotinib (MMB) versus best available therapy (BAT) in patients with myelofibrosis (MF) previously treated with ruxolitinib (RUX). J Clin Oncol. 2017;35(15_suppl):7001.

    Article  Google Scholar 

  68. •• Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, et al. SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-naive patients with myelofibrosis. J Clin Oncol. 2017;35(34):3844–50. Randomized trial with momelotinib in MF.

    Article  PubMed  Google Scholar 

  69. Mesa RA, Passamonti F. Individualizing care for patients with myeloproliferative neoplasms: integrating genetics, evolving therapies, and patient-specific disease burden. Am Soc Clin Oncol Educ Book. 2016;35:e324–35.

    Article  PubMed  Google Scholar 

  70. •• Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol. 2017;4(7):e317–e24. Randomized trial with fedratinib in ruxolitinib-treated MF.

    Article  PubMed  Google Scholar 

  71. •• Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol. 2015;1(5):643–51. Randomized trial with fedratinib in MF.

    Article  PubMed  Google Scholar 

  72. Mesa RA, Vannucchi AM, Mead A, Egyed M, Szoke A, Suvorov A, et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol. 2017;4(5):e225–e36.

    Article  PubMed  Google Scholar 

  73. •• Talpaz M, Mascarenhas J, Hoffman R, Gerds AT, Stein B, Gupta V, et al. Pacritinib (Pac) vs best available therapy (Bat), including ruxolitinib, in patients (Pts) with myelofibrosis (Mf) and baseline thrombocytopenia: focus on anemia in the phase 3 PERSIST-2 Trial. Haematologica. 2017;102:279–80. Randomized trial with pacritinib in MF.

    Google Scholar 

  74. •• Tefferi A, Al-Ali HK, Barosi G, Devos T, Gisslinger H, Jiang Q, et al. A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence. Leukemia. 2017;31(5):1252. Randomized trial with pomalidomide in MF.

    Article  PubMed  CAS  Google Scholar 

  75. Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009;27(27):4563–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  76. Elena C, Passamonti F, Rumi E, Malcovati L, Arcaini L, Boveri E, et al. Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. Haematologica. 2011;96(1):167–70.

    Article  PubMed  Google Scholar 

  77. Gale RP, Barosi G, Barbui T, Cervantes F, Dohner K, Dupriez B, et al. What are RBC-transfusion-dependence and -independence? Leuk Res. 2011;35(1):8–11.

    Article  PubMed  CAS  Google Scholar 

  78. Gale RP, Barosi G, Barbui T, Cervantes F, Dohner K, Dupriez B, et al. RBC-transfusion guidelines update. Leuk Res. 2012;36(5):659–60.

    Article  PubMed  CAS  Google Scholar 

  79. Bacigalupo A, Soraru M, Dominietto A, Pozzi S, Geroldi S, Van Lint MT, et al. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant. 2010;45(3):458–63.

    Article  PubMed  CAS  Google Scholar 

  80. Shanavas M, Popat U, Michaelis LC, Fauble V, McLornan D, Klisovic R, et al. Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to Janus kinase 1/2 inhibitors. Biol Blood Marrow Transplant. 2016;22(3):432–40.

    Article  PubMed  CAS  Google Scholar 

  81. Alchalby H, Yunus DR, Zabelina T, Kobbe G, Holler E, Bornhauser M, et al. Risk models predicting survival after reduced-intensity transplantation for myelofibrosis. Br J Haematol. 2012;157(1):75–85.

    Article  PubMed  Google Scholar 

  82. Cervantes F, Dupriez B, Passamonti F, Vannucchi AM, Morra E, Reilly JT, et al. Improving survival trends in primary myelofibrosis: an international study. J Clin Oncol. 2012;30(24):2981–7.

    Article  PubMed  Google Scholar 

  83. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Cazzola M, et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood. 2010;116(15):2857–8.

    Article  PubMed  CAS  Google Scholar 

  84. Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015;100(9):1139–45.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  85. Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018; https://doi.org/10.1038/s41375-018-0077-1.

Download references

Author information

Authors and Affiliations

  1. Department of Medicine and Surgery, University of Insubria, Varese, Italy

    Francesco Passamonti, Barbara Mora, Daniela Barraco & Margherita Maffioli

  2. Hematology, Department of Specialistic Medicine, Ospedale di Circolo, ASST Sette Laghi, Varese, Italy

    Francesco Passamonti

  3. Hematology, Dipartimento di Medicina e Chirurgia, University of Insubria, Via Guicciardini, 21100, Varese, Italy

    Francesco Passamonti

Authors
  1. Francesco Passamonti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barbara Mora
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniela Barraco
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Margherita Maffioli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francesco Passamonti.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Myeloproliferative Neoplasms

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Passamonti, F., Mora, B., Barraco, D. et al. Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis. Curr Hematol Malig Rep 13, 173–182 (2018). https://doi.org/10.1007/s11899-018-0453-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-018-0453-y

Keywords

Search

Navigation